AstraZeneca Loses Bid To Overturn Prilosec Ruling

Law360, New York (June 10, 2008, 12:00 AM EDT) -- The U.S. Court of Appeals for the Federal Circuit has upheld a lower court ruling that Mylan Laboratories Inc.'s generic version of the gastric-acid inhibitor Prilosec does not infringe rival AstraZeneca AB's patents.

The appeals court on Tuesday affirmed the U.S. District Court for the Southern District of New York's May 2007 ruling that the company's omeprazole delayed-release capsules did not infringe two AstraZeneca patents for the branded version.

The patents-in-suit are U.S. Patent Numbers 4,786,505 and 4,853,230, which cover the Prilosec formulation.

“Once again, we...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.